KIORA PHARMACEUTICALS reported that Baselake Partners, Baselake Management and David Paolella each hold or may share voting and dispositive power over 257,500 common shares, representing 5.8% of the outstanding stock. The passive designation matters to investors because the group certified it was not seeking to influence Kiora’s control.
Key Highlights
- Baselake Partners, Baselake Management and David Paolella each report a 5.8% position in KIORA PHARMACEUTICALS.
- KIORA’s reported security is common stock with a $0.01 par value.
- The three reporting parties signed their joint filing statement on September 17, 2026.
KIORA PHARMACEUTICALS INC. (NASDAQ: KPRX) is a Pharmaceuticals: Major company. Baselake Partners, LP, Baselake Management, LLC and David Paolella report shared voting and dispositive power over 257,500 Kiora common shares, a position identified as passive.
Baselake Group Reports 257,500 Shares
The reported position is tied directly to Baselake Partners, which is described as the fund. Baselake Management serves as the fund’s Investment manager, while David Paolella serves as its managing member. The three parties each list 257,500 shares and a 5.8% interest, based on 4,424,387 Kiora shares issued and outstanding as of August 5, 2026. The securities are KIORA PHARMACEUTICALS common stock with a $0.01 par value. The position was reported as of September 10, 2026. The certification also excludes participation in a transaction intended to produce that result, apart from activities solely connected with a nomination under Section 240.14a-11. The report says the three parties may be deemed to share voting and dispositive power because of their relationships. Each disclaims beneficial ownership except to the extent of its pecuniary interest. Baselake Partners, Baselake Management and Paolella signed the joint filing statement on September 17, 2026.
FAQs
Q: What stake did Baselake Partners report in Kiora Pharmaceuticals?
A: Baselake Partners reported 257,500 Kiora Pharmaceuticals common shares. The position represented 5.8% of the shares outstanding used for the report’s calculation.
Q: Is the Kiora Pharmaceuticals position intended to influence control?
A: The reported Kiora Pharmaceuticals position was certified as passive. The parties stated the securities were not held to change or influence control of Kiora.
Q: Who shares voting power over the Kiora shares?
A: Baselake Partners, Baselake Management and David Paolella may be deemed to share voting and dispositive power. Their relationship reflects the fund, its investment manager and its managing member.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.